TAmiRNA experts to host Meet the Professor sessions at ASBMR Annual Meeting 2017 in Denver
Press Release | TAmiRNA GmbH
SEPTEMBER 06, 2017
Vienna, Austria:- Innovative biotech company TAmiRNA will offer two of its respected experts on the use of circulating microRNA technologies to combat osteoporosis and musculoskeletal diseases for ‘Meet the Professor’ sessions at this year’s annual meeting of the American Society for Bone and Mineral Research (ASMBR 2017) in Denver, Colorado.
TAmiRNA GmbH Scientific Advisor, Johannes Grillari, Ph.D., will be first to host a session. On “Aging Bone and MiRs” on day two of the conference (Saturday, Sept. 9, 11:00 am – 12:00 pm).
The following day (Sunday, Sept. 10, 11:00 am – 12:00 pm), TAmiRNA CEO Matthias Hackl, PhD., will hold a disciussion on “Non-Coding RNAs”.
“We are looking forward to taking part in these Meet-the-Professor Sessions, which are small, informal discussions that are designed to provide an opportunity for ASBMR attendees to interact with experts in an intimate setting and discuss specific clinical and research topics,” said Dr. Hackl.
“ASBMR is one of our favourite events. We have been attending for the last five years. Projects in which TAmiRNA has been involved have been selected for Investigator Awards in 2014 and 2016.” Dr. Hackl noted.
A TAmiRNA exhibiton stand at Booth 435 in the Exhibit Hall will showcase a range of the company’s innovative products and services, such as its osteomiR™ microRNA testing kit to detect novel serum biomarker candidates for predicting fracture risk in osteoporosis.
“We are looking forward to discussons with our peers from biotech and pharma companies participating in clinical studies in musculoskeletal and cardiovascular disease, academic and clinical research groups,” said Dr. Johannes Grillari.
Privately owned and headquartered in Vienna, TAmiRNA GmbH is a biotech company specialized in the identification and validation of non-coding RNAs as biomarkers for age-related diseases. The mission of TAmiRNA is to provide clinically useful biomarkers to improve and prolong patient stability, health and quality of life with increasing age.
TAmiRNA specializes in technologies for profiling levels of blood-circulating microRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for early diagnosis and prognosis of disease, or as companion diagnostic tests to support treatment decisions.
TAmiRNA’s pipeline includes developments in osteoporosis, cardiovascular disease, type-2 diabetes, and cancer, which aim to provide ‘microRNA kit’ solutions that enable users to quantify the levels of specific microRNA combinations and platelet function in serum, plasma, urine or other biofluids. The company initially developed kits for bone disease (osteomiR) and cardiovascular disease (thrombomiR).
TAmiRNA also offers contract research services for companies in need of targeted biomarker development. Customers include biopharma companies with drug development programs in human and veterinary medicine, medtech companies and clinical research groups.
More information available at: www.tamirna.com
About ASBMR 2017
The American Society for Bone and Mineral Research is one of the world’s leading professional, scientific and medical organizations for bone and mineral researchers and clinicians and forms a highly-effective voice for advocacy and science policy for nearly 4,000 scientists and clinicians from 60 countries.
The society’s annual meeting attracts leading scientists, researchers and laboratories from around the globe to exchange latest scientific insights, connect with colleagues and learn about leading edge products and services.
The 2017 ASBMR meeting is a four-day event opening September 8 at the Colorado Convention Center in Denver. It will feature more than 100 presentation and discussion sessions, including hands-on workshops, plenary presentations and topical symposia.
Sessions of Interest include plenary lectures on “Cellular Senescence: Yin and Yang” with Dr. Judith Campisi and the Louis V. Avioli Lecture by Dr. Stavros Manolagas, on “The Quest for Osteoporosis Mechanisms: How Far We’ve Come, How Much Further We Need to Go”.
The 2017 conference will also be webcast via Live Online, ASBMR’s virtual conference experience.
More information available at: www.asbmr.org/meetings/annualmeeting.aspx
Dr. Elisabeth Schraml, Scientific Communications, TAmiRNA GmbH
Tel: +43 (0)660 420 58 56